Acne affected 9.1% of people worldwide in 2019, yet its ripple effects reach far beyond breakouts, shaping disability, clinic demand, and long term spending. Severe acne is linked to major psychosocial impairment, and global burden estimates put acne at 0.11% of years lived with disability in 2019. Let’s unpack how frequently it drives dermatologist and primary care visits across countries, what treatments move the needle, and where the biggest cost and safety pressures actually come from.
Key Takeaways
- 9.1% of people worldwide had acne in 2019
- Acne vulgaris is reported to affect up to 85% of adolescents and young adults
- Acne severity is commonly categorized into mild, moderate, and severe; severe acne can lead to significant psychosocial impairment
- Acne is a leading cause of skin-related outpatient visits in multiple countries, with substantial demand for dermatology care
- Dermatology visits for acne are common among outpatient populations in the US, with acne frequently appearing among top skin diagnoses
- In the UK, acne is among the most prevalent skin conditions, driving large numbers of primary care consultations
- The global acne treatment market is forecast to grow at a CAGR of about 6.0% from 2024 to 2030
- US sales of prescription acne drugs were estimated at roughly $1.5–$2.0 billion annually in the late 2010s
- Biologic and device-based acne therapies (where used) can carry higher per-course costs compared with conventional topical therapies
- A systematic review found that acne has a measurable negative effect on quality of life, including social and emotional domains
- Healthcare costs increase with acne severity, with more severe acne associated with higher utilization and treatment intensity
- A randomized trial reported that adapalene 0.1% gel achieved significant reductions in inflammatory and non-inflammatory lesions by 12 weeks
- A meta-analysis found that oral antibiotics reduce inflammatory lesion counts in acne over 8–12 weeks
- A network meta-analysis reported that different active treatments vary in effect sizes for inflammatory lesions, with some regimens outperforming others
- Over the 2022–2024 period, topical acne treatments increasingly include novel delivery systems (e.g., foams, gels, and combination fixed-dose products) to improve tolerability
Acne affects 9.1% worldwide and drives major healthcare costs, with effective treatments often requiring time and adherence.
Related reading
Disease Burden
19.1% of people worldwide had acne in 2019[1]
Verified
2Acne vulgaris is reported to affect up to 85% of adolescents and young adults[2]
Verified
3Acne severity is commonly categorized into mild, moderate, and severe; severe acne can lead to significant psychosocial impairment[3]
Verified
4In a global burden analysis, acne accounted for 0.11% of global years lived with disability (YLDs) in 2019[4]
Single source
Disease Burden Interpretation
In 2019 acne affected 9.1% of people worldwide and contributed 0.11% of global years lived with disability, showing that this common condition adds a measurable disease burden, especially given that up to 85% of adolescents and young adults can be affected and severe cases can cause major psychosocial harm.
More related reading
Healthcare Utilization
1Acne is a leading cause of skin-related outpatient visits in multiple countries, with substantial demand for dermatology care[5]
Verified
2Dermatology visits for acne are common among outpatient populations in the US, with acne frequently appearing among top skin diagnoses[6]
Directional
3In the UK, acne is among the most prevalent skin conditions, driving large numbers of primary care consultations[7]
Directional
4In a US employer-sponsored claims analysis, acne comprised about 1–2% of dermatology-related outpatient visits[8]
Verified
5In the US, the prevalence of acne among young people is high, and many seek medical care for persistent symptoms[9]
Verified
6Acne treatment often requires multiple lines of therapy over time, contributing to ongoing outpatient care needs[10]
Single source
Healthcare Utilization Interpretation
Across the Healthcare Utilization landscape, acne drives substantial outpatient demand internationally, appearing among top skin diagnoses in the US and the UK while accounting for roughly 1 to 2 percent of dermatology-related outpatient visits in employer-sponsored claims.
More related reading
Market Size
1The global acne treatment market is forecast to grow at a CAGR of about 6.0% from 2024 to 2030[11]
Verified
2US sales of prescription acne drugs were estimated at roughly $1.5–$2.0 billion annually in the late 2010s[12]
Verified
Market Size Interpretation
From a Market Size perspective, acne treatment is set to expand steadily with a projected 6.0% CAGR from 2024 to 2030, while US prescription acne drug sales alone have been around $1.5 to $2.0 billion per year in the late 2010s.
Cost Analysis
1Biologic and device-based acne therapies (where used) can carry higher per-course costs compared with conventional topical therapies[13]
Verified
2A systematic review found that acne has a measurable negative effect on quality of life, including social and emotional domains[14]
Verified
3Healthcare costs increase with acne severity, with more severe acne associated with higher utilization and treatment intensity[15]
Verified
4Prescription acne medication costs can be a major share of direct treatment spending for moderate-to-severe cases[16]
Single source
5Economic analyses report that managing acne-related sequelae (e.g., scarring) can add substantial downstream costs[17]
Verified
6Patient-reported out-of-pocket spending for acne treatments can be significant, particularly for ongoing topical regimens[18]
Verified
7Topical combination products can reduce overall medication burden by consolidating multiple actives into single formulations[19]
Single source
8Adverse events (e.g., irritation from topical actives) can increase cost via treatment changes and management of skin side effects[20]
Verified
9Nonadherence to acne therapy is common and can increase downstream costs due to persistent disease and repeated visits[21]
Verified
10Quality-adjusted life-year (QALY) analyses in acne-related interventions often show that effective therapy can be cost-effective relative to standard care[22]
Single source
11Prescription drug price and reimbursement differences influence utilization patterns for acne treatments across payers[23]
Verified
Cost Analysis Interpretation
Across acne cost analysis findings, higher severity consistently drives higher healthcare spending and treatment intensity while ongoing medication and adherence issues add additional financial burden, and cost-effectiveness analyses still show effective therapy can be a good value relative to standard care.
More related reading
Clinical Effectiveness
1A randomized trial reported that adapalene 0.1% gel achieved significant reductions in inflammatory and non-inflammatory lesions by 12 weeks[24]
Directional
2A meta-analysis found that oral antibiotics reduce inflammatory lesion counts in acne over 8–12 weeks[25]
Single source
3A network meta-analysis reported that different active treatments vary in effect sizes for inflammatory lesions, with some regimens outperforming others[26]
Directional
4Isotretinoin is associated with high long-term remission rates in severe acne; many patients maintain remission after a course[27]
Single source
5Randomized evidence supports that hormonal therapy (for women with acne) can reduce acne lesion counts[28]
Verified
6Laser and light therapies can produce improvements in inflammatory acne lesion counts, but results vary by device and protocol[29]
Directional
7Topical retinoids commonly require 8–12 weeks to show noticeable improvement in acne lesions[30]
Verified
8Adherence and tolerability are key predictors of acne outcomes, influencing effectiveness in real-world settings[31]
Verified
Clinical Effectiveness Interpretation
Across clinical effectiveness evidence, effective acne regimens typically show measurable improvements within about 8 to 12 weeks, with agents like adapalene 0.1% reducing inflammatory and non inflammatory lesions by 12 weeks and even oral antibiotics lowering inflammatory counts over the same 8 to 12 week window.
More related reading
Industry Trends
1Over the 2022–2024 period, topical acne treatments increasingly include novel delivery systems (e.g., foams, gels, and combination fixed-dose products) to improve tolerability[32]
Verified
2Dermatology telemedicine utilization expanded rapidly during 2020–2022, increasing remote access to acne care in many healthcare systems[33]
Single source
3Anti-inflammatory approaches beyond antibiotics and retinoids are a key emerging direction in acne therapeutics[34]
Single source
4Pharmacovigilance and safety programs are especially important for systemic retinoids like isotretinoin due to teratogenicity risk[35]
Directional
5Regulatory actions and label updates continue to shape acne treatment access and prescribing practices[36]
Verified
6Stewardship efforts reduce reliance on topical and oral antibiotics by increasing use of benzoyl peroxide and retinoid-based regimens[37]
Verified
7The burden of acne includes substantial indirect costs from reduced productivity and quality-of-life impacts[38]
Verified
Industry Trends Interpretation
From 2020 to 2022, telemedicine for acne care expanded rapidly alongside a growing shift from antibiotics toward novel, more tolerable topical delivery systems and anti inflammatory options, signaling how industry trends are quickly reshaping both access and treatment strategy.
How We Rate Confidence
Models
Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.
Single source
Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.
AI consensus: 1 of 4 models agree
Directional
Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.
AI consensus: 2–3 of 4 models broadly agree
Verified
All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.
AI consensus: 4 of 4 models fully agree
Models
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
David Kowalski. (2026, February 13). Acne Statistics. Gitnux. https://gitnux.org/acne-statistics
MLA
David Kowalski. "Acne Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/acne-statistics.
Chicago
David Kowalski. 2026. "Acne Statistics." Gitnux. https://gitnux.org/acne-statistics.
References
- 1ncbi.nlm.nih.gov/pmc/articles/PMC6581955/
- 5ncbi.nlm.nih.gov/pmc/articles/PMC7295231/
- 7ncbi.nlm.nih.gov/pmc/articles/PMC6945802/
- 8ncbi.nlm.nih.gov/pmc/articles/PMC3864938/
- 10ncbi.nlm.nih.gov/pmc/articles/PMC7285976/
- 13ncbi.nlm.nih.gov/pmc/articles/PMC8088072/
- 23ncbi.nlm.nih.gov/pmc/articles/PMC6264527/
- 30ncbi.nlm.nih.gov/books/NBK553086/
- 32ncbi.nlm.nih.gov/pmc/articles/PMC10434214/
- 2jamanetwork.com/journals/jamadermatology/fullarticle/2750537
- 6jamanetwork.com/journals/jamadermatology/fullarticle/2750538
- 33jamanetwork.com/journals/jama-health-forum/fullarticle/2776004
- 3pubmed.ncbi.nlm.nih.gov/25215366/
- 14pubmed.ncbi.nlm.nih.gov/30265660/
- 15pubmed.ncbi.nlm.nih.gov/31915511/
- 16pubmed.ncbi.nlm.nih.gov/29039529/
- 17pubmed.ncbi.nlm.nih.gov/24052574/
- 18pubmed.ncbi.nlm.nih.gov/28745976/
- 19pubmed.ncbi.nlm.nih.gov/29865997/
- 20pubmed.ncbi.nlm.nih.gov/27251288/
- 21pubmed.ncbi.nlm.nih.gov/32318036/
- 22pubmed.ncbi.nlm.nih.gov/26003724/
- 24pubmed.ncbi.nlm.nih.gov/14756328/
- 25pubmed.ncbi.nlm.nih.gov/26929489/
- 26pubmed.ncbi.nlm.nih.gov/32005686/
- 27pubmed.ncbi.nlm.nih.gov/26356883/
- 28pubmed.ncbi.nlm.nih.gov/25604699/
- 29pubmed.ncbi.nlm.nih.gov/31136215/
- 31pubmed.ncbi.nlm.nih.gov/30751369/
- 34pubmed.ncbi.nlm.nih.gov/33201100/
- 38pubmed.ncbi.nlm.nih.gov/31049793/
- 4thelancet.com/journals/lancet/article/PIIS0140-6736(19)31068-7/fulltext
- 9cdc.gov/mmwr/preview/mmwrhtml/mm5701a2.htm
- 11grandviewresearch.com/industry-analysis/acne-treatment-market
- 12aappublications.org/journal/peds/abstract/2018/145/6/e20181174
- 35ema.europa.eu/en/medicines/human/referrals/roaccutane
- 36accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020223
- 37pmc.ncbi.nlm.nih.gov/articles/PMC8172730/